Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32


CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.

Ng SR, Rideout WM 3rd, Akama-Garren EH, Bhutkar A, Mercer KL, Schenkel JM, Bronson RT, Jacks T.

Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):513-521. doi: 10.1073/pnas.1821893117. Epub 2019 Dec 23.


A Modular Assembly Platform for Rapid Generation of DNA Constructs.

Akama-Garren EH, Joshi NS, Tammela T, Chang GP, Wagner BL, Lee DY, Rideout WM 3rd, Papagiannakopoulos T, Xue W, Jacks T.

Sci Rep. 2016 Feb 18;6:16836. doi: 10.1038/srep16836.


Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. doi: 10.1073/pnas.1411848112. Epub 2015 Mar 3.


Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

Pennacchietti S, Cazzanti M, Bertotti A, Rideout WM 3rd, Han M, Gyuris J, Perera T, Comoglio PM, Trusolino L, Michieli P.

Cancer Res. 2014 Nov 15;74(22):6598-609. doi: 10.1158/0008-5472.CAN-14-0761. Epub 2014 Sep 12.


Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy.

Zhou Y, Rideout WM 3rd, Bressel A, Yalavarthi S, Zi T, Potz D, Farlow S, Brodeur J, Monti A, Reddipalli S, Xiao Q, Bottega S, Feng B, Chiu MI, Bosenberg M, Heyer J.

PLoS One. 2014 Aug 27;9(8):e105886. doi: 10.1371/journal.pone.0105886. eCollection 2014.


MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C.

Cancer Res. 2014 Mar 15;74(6):1857-69. doi: 10.1158/0008-5472.CAN-13-2340-T. Epub 2014 Jan 21.


Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.

Zhou Y, Rideout WM 3rd, Zi T, Bressel A, Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, Bosenberg M, Jacks T, Clark SC, Depinho RA, Robinson MO, Heyer J.

Nat Biotechnol. 2010 Jan;28(1):71-8. doi: 10.1038/nbt.1595. Epub 2009 Dec 20.


Global loss of imprinting leads to widespread tumorigenesis in adult mice.

Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM 3rd, Jaenisch R.

Cancer Cell. 2005 Oct;8(4):275-85. Erratum in: Cancer Cell. 2005 Nov;8(5):433. Cancer Cell. 2006 Jan;9(1):69.


Nuclear transplantation, embryonic stem cells and the potential for cell therapy.

Hochedlinger K, Rideout WM, Kyba M, Daley GQ, Blelloch R, Jaenisch R.

Hematol J. 2004;5 Suppl 3:S114-7. Review.


Dnmt1 expression in pre- and postimplantation embryogenesis and the maintenance of IAP silencing.

Gaudet F, Rideout WM 3rd, Meissner A, Dausman J, Leonhardt H, Jaenisch R.

Mol Cell Biol. 2004 Feb;24(4):1640-8.


Cyclin E ablation in the mouse.

Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P.

Cell. 2003 Aug 22;114(4):431-43.


Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy.

Rideout WM 3rd, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R.

Cell. 2002 Apr 5;109(1):17-27.


Nuclear cloning and epigenetic reprogramming of the genome.

Rideout WM 3rd, Eggan K, Jaenisch R.

Science. 2001 Aug 10;293(5532):1093-8. Review.


Epigenetic instability in ES cells and cloned mice.

Humpherys D, Eggan K, Akutsu H, Hochedlinger K, Rideout WM 3rd, Biniszkiewicz D, Yanagimachi R, Jaenisch R.

Science. 2001 Jul 6;293(5527):95-7.


Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation.

Eggan K, Akutsu H, Loring J, Jackson-Grusby L, Klemm M, Rideout WM 3rd, Yanagimachi R, Jaenisch R.

Proc Natl Acad Sci U S A. 2001 May 22;98(11):6209-14. Epub 2001 May 1.


Generation of mice from wild-type and targeted ES cells by nuclear cloning.

Rideout WM 3rd, Wakayama T, Wutz A, Eggan K, Jackson-Grusby L, Dausman J, Yanagimachi R, Jaenisch R.

Nat Genet. 2000 Feb;24(2):109-10. No abstract available.


Developmental potential of mouse primordial germ cells.

Kato Y, Rideout WM 3rd, Hilton K, Barton SC, Tsunoda Y, Surani MA.

Development. 1999 May;126(9):1823-32.


Mapping of the Fas-associated factor 1 gene, Faf1, to mouse chromosome 4C6 by FISH.

Kikyo N, Rideout WM 3rd, Tada T, Tada M, Surani MA.

Mamm Genome. 1997 Mar;8(3):224-5. No abstract available.


Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR.

Gonzalgo ML, Liang G, Spruck CH 3rd, Zingg JM, Rideout WM 3rd, Jones PA.

Cancer Res. 1997 Feb 15;57(4):594-9.


Mutagenicity of nitric oxide is not caused by deamination of cytosine or 5-methylcytosine in double-stranded DNA.

Schmutte C, Rideout WM 3rd, Shen JC, Jones PA.

Carcinogenesis. 1994 Dec;15(12):2899-903.


Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation.

Rideout WM 3rd, Eversole-Cire P, Spruck CH 3rd, Hustad CM, Coetzee GA, Gonzales FA, Jones PA.

Mol Cell Biol. 1994 Sep;14(9):6143-52.


The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA.

Shen JC, Rideout WM 3rd, Jones PA.

Nucleic Acids Res. 1994 Mar 25;22(6):972-6.


Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.

Spruck CH 3rd, Rideout WM 3rd, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, et al.

Cancer Res. 1993 Mar 1;53(5):1162-6. Erratum in: Cancer Res 1993 May 15;53(10 Suppl):2427.


DNA methylation and cancer.

Spruck CH 3rd, Rideout WM 3rd, Jones PA.

EXS. 1993;64:487-509. Review. No abstract available.


High frequency mutagenesis by a DNA methyltransferase.

Shen JC, Rideout WM 3rd, Jones PA.

Cell. 1992 Dec 24;71(7):1073-80.


Absence of p53 gene mutations in primary nasopharyngeal carcinomas.

Spruck CH 3rd, Tsai YC, Huang DP, Yang AS, Rideout WM 3rd, Gonzalez-Zulueta M, Choi P, Lo KW, Yu MC, Jones PA.

Cancer Res. 1992 Sep 1;52(17):4787-90.


Methylation, mutation and cancer.

Jones PA, Rideout WM 3rd, Shen JC, Spruck CH, Tsai YC.

Bioessays. 1992 Jan;14(1):33-6. Review.


5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene.

Rideout WM 3rd, Coetzee GA, Olumi AF, Spruck CH, Jones PA.

Princess Takamatsu Symp. 1991;22:207-19. Review.


5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes.

Rideout WM 3rd, Coetzee GA, Olumi AF, Jones PA.

Science. 1990 Sep 14;249(4974):1288-90.


De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines.

Jones PA, Wolkowicz MJ, Rideout WM 3rd, Gonzales FA, Marziasz CM, Coetzee GA, Tapscott SJ.

Proc Natl Acad Sci U S A. 1990 Aug;87(16):6117-21.


Plasminogen activator regulation by transforming growth factor-beta in normal and neoplastic human urothelium.

Hiti AL, Rideout WM 3rd, Laug WE, Jones PA.

Cancer Commun. 1990;2(3):123-8.


Supplemental Content

Loading ...
Support Center